Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPSE | Q9Y251 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6234424 | 0.87 | HPSE (0.52) | HPSEALDH1A1SMN1; SMN2CYP1A2CYP2C19 | |
| SCHEMBL10098857 | 0.85 | ALDH1A1 (0.51) | HPSEALDH1A1SMN1; SMN2CYP1A2CYP2C19 | |
| SCHEMBL1562841 | 0.85 | HPSE (0.60) | HPSEALDH1A1SMN1; SMN2CYP1A2CYP2C19 | |
| SCHEMBL18493192 | 0.84 | HPSE (0.50) | HPSEALDH1A1SMN1; SMN2CYP1A2CYP2C19 | |
| SCHEMBL5651138 | 0.84 | HPSE (0.50) | HPSEALDH1A1SMN1; SMN2CYP1A2CYP2C19 | |
| SCHEMBL1562499 | 0.84 | ALDH1A1 (0.54) | HPSEALDH1A1SMN1; SMN2CYP1A2CYP2C19 | |
| SCHEMBL25734944 | 0.84 | HPSE (0.50) | HPSEALDH1A1SMN1; SMN2CYP1A2CYP2C19 | |
| SCHEMBL3072842 | 0.81 | HPSE (0.56) | HPSEALDH1A1SMN1; SMN2CYP1A2CYP2C19 | |
| SCHEMBL5531874 | 0.81 | ALDH1A1 (0.53) | HPSEALDH1A1SMN1; SMN2CYP1A2CYP2C19 | |
| SCHEMBL12678273 | 0.81 | HPSE (0.47) | HPSEALDH1A1SMN1; SMN2CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022061168-A1 | E-SELECTIN TARGETING AGENTS | GLYCOMIMETICS, INC. (US) | 2022-03-24 | — | — | WO | disclosed |
| WO-2021222777-A1 | CD33 LIGANDS SUITABLE FOR INCORPORATION INTO CARRIERS | MAGNANI JOHN L (US) | 2021-11-04 | — | — | WO | disclosed |
| WO-2021222767-A1 | CD33 LIGANDS SUITABLE FOR INCORPORATION INTO CARRIERS | GLYCOMIMETICS, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| US-8575391-B2 | 5-substituted-2-phenylamino benzamides as MEK inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2013-11-05 | — | — | US | disclosed |
| EP-1780197-B9 | 5-SUBSTITUTED-2-PHENYLAMINO BENZAMIDES AS MEK INHIBITORS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2011-04-06 | — | — | EP | disclosed |
| EP-1780197-B1 | 5-SUBSTITUTED-2-PHENYLAMINO BENZAMIDES AS MEK INHIBITORS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2010-10-20 | — | — | EP | disclosed |
| US-7772286-B2 | Polyvinyl alcohol copolymers comprising biomolecules | EYESENSE AG (CH) | 2010-08-10 | — | — | US | disclosed |
| US-7772286-B2 | Polyvinyl alcohol copolymers comprising biomolecules | EYESENSE AG (CH) | 2010-08-10 | — | — | US | disclosed |
| US-20100197676-A1 | 5-Substituted-2-Phenylamino Benzamides as Mek Inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-08-05 | — | — | US | disclosed |
| US-7745663-B2 | 5-Substituted-2-phenylamino benzamides as MEK inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-06-29 | — | — | US | disclosed |
| US-20090233915-A1 | 5-Substituted-2-Phenylamino Benzamides as MEK Inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-09-17 | — | — | US | disclosed |
| US-20090162290-A1 | METHOD FOR THE SYNTHESIS OF PENTA-PENDANT ENANTIOMER-PURE CHELATORS AND PROCESS FOR THERAPEUTICALLY ACTIVE BIOCONJUGATES PREPARATION BY A COVALENT BINDING THEREOF | THERAPHARM GMBH | 2009-06-25 | — | — | US | disclosed |
| US-20090162290-A1 | METHOD FOR THE SYNTHESIS OF PENTA-PENDANT ENANTIOMER-PURE CHELATORS AND PROCESS FOR THERAPEUTICALLY ACTIVE BIOCONJUGATES PREPARATION BY A COVALENT BINDING THEREOF | THERAPHARM GMBH | 2009-06-25 | — | — | US | disclosed |
| US-20090036353-A1 | Insulin Derivatives Conjugated with Structurally Well Defined Branched Polymers | NOVO NORDISK A/S (DK) | 2009-02-05 | — | — | US | disclosed |
| US-20090036353-A1 | Insulin Derivatives Conjugated with Structurally Well Defined Branched Polymers | NOVO NORDISK A/S (DK) | 2009-02-05 | — | — | US | disclosed |
| US-7479530-B2 | Polymer having charged units | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2009-01-20 | — | — | US | disclosed |
| US-7479530-B2 | Polymer having charged units | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2009-01-20 | — | — | US | disclosed |
| EP-1780197-A1 | 5-SUBSTITUTED-2-PHENYLAMINO-BENZAMIDE AS MEK INHIBITOR | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-05-02 | — | — | EP | disclosed |
| WO-2007028639-A1 | METHOD FOR THE SYNTHESIS OF PENTAPENDANT ENANTIOMER-PURE CHELATORS AND PROCESS FOR THERAPEUTICALLY ACTIVE BIO-CONJUGATES PREPARATION BY A COVALENT BINDING OF THEREOF | THERAPHARM GMBH (CH) | 2007-03-15 | — | — | WO | disclosed |
| US-6828392-B2 | For use as solid supports for organic synthesis, for enzymatic assays, for immobilization of biomolecules, for controlled release of drugs, and for chromatographic separations | CARLSBERG A/S (DK) | 2004-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090162290-A1 | METHOD FOR THE SYNTHESIS OF PENTA-PENDANT ENANTIOMER-PURE CHELATORS AND PROCESS FOR THERAPEUTICALLY ACTIVE BIOCONJUGATES PREPARATION BY A COVALENT BINDING THEREOF | C5, C3AR1, SPR | HPSE 1587/4885ALDH1A1 733/4885SMN1; SMN2 3717/4885 |
| US-20100197676-A1 | 5-Substituted-2-Phenylamino Benzamides as Mek Inhibitors | BRAF, RAF1, NRAS | HPSE 4173/4885ALDH1A1 680/4885SMN1; SMN2 2741/4885 |
| US-20090233915-A1 | 5-Substituted-2-Phenylamino Benzamides as MEK Inhibitors | BRAF, RAF1, NRAS | HPSE 4173/4885ALDH1A1 680/4885SMN1; SMN2 2741/4885 |
| US-20090036353-A1 | Insulin Derivatives Conjugated with Structurally Well Defined Branched Polymers | INSR, IAPP, IGF1R | HPSE 544/4885ALDH1A1 4305/4885SMN1; SMN2 1930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.